TISSUE AND PERIPHERAL T-CELL REPERTOIRE PREDICTS IMMUNOTHERAPY RESPONSE AND PROGRESSION-FREE SURVIVAL IN NSCLC PATIENTS

Manuel Pino-González^{1#}, Martín Lázaro-Quintela^{1,2#}, Irene Alonso-Álvarez¹, María Gallardo-Gómez¹, Laura Juaneda-Magdalena¹, Alejandro Francisco-Fernández³, Silvia Calabuig-Fariñas^{4,5,6}, Eloisa Jantus-Lewintre^{5,6,7}, Mónica Martínez-Fernández^{1*}

- Translational Oncology Group. Galicia Sur Health Research Institute (IIS Galicia Sur). SERGAS UVIGO. Hospital Álvaro Cunqueiro. Carretera Clara Campoamor, 341. 36213 (Vigo), Spain.
- Medical Oncology Service. Hospital Álvaro Cunqueiro. Carretera Clara Campoamor, 341. 36213 (Vigo), Spain.
- Medical Oncology Service. Hospital Provincial de Pontevedra. Calle Doutor Loureiro Crespo, 2. 36001 (Pontevedra), Spain.
- 4. Department of Pathology. Universitat de València, 46010 (Valencia), Spain.
- 5. Centro de Investigación Biomédica en Red Cáncer (CIBERONC). Valencia, Spain.
- Mixed Unit TRIAL. General University Hospital of Valencia Research Foundation and Príncipe Felipe Research Center. Hospital General Universitario de Valencia, 46014 (Valencia), Spain.
- Department of Biotechnology. Universitat Politècnica de València, 46022 (Valencia), Spain.

Equal contribution

*Corresponding author: Mónica Martínez-Fernández. Translational Oncology Group. Galicia Sur Health Research Institute (IIS Galicia Sur). SERGAS-UVIGO. Hospital Álvaro Cunqueiro. Estrada de Clara Campoamor, 341, 36213 (Vigo), Spain.

Email: monica.martinez@iisgaliciasur.es

Running title

TCR Predicts Immunotherapy Response and Progression in NSCLC Patients

Keywords

non-small cell lung cancer; immunotherapy; predictive biomarker; immunotherapy response; T cell receptor; TCR repertoire.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Immunotherapy has opened new avenues of treatment for patients with advanced non-small cell lung cancer (NSCLC) without previous hope of survival. Unfortunately, only a small percentage of patients benefit from it, and it is still not well understood which tumor characteristics can be used to predict immunotherapy response. As the key cellular effectors of antitumor immunity, T cells are endowed with specialized T cell receptors (TCRs) to recognize and eliminate cancer cells. Here, we evaluated the potential of TCR repertoire as a predictive biomarker in patients treated with immunotherapy. With this aim, advanced NSCLC patients treated with immunotherapy at first-line were included. After obtaining peripheral blood and tissue samples at baseline, next-generation sequencing targeting TCR β/γ was performed. Beyond TCR metrics, clonal space of the most frequent clones was determined. We found a positive association between uneven tumor-infiltrating TCRB repertoire and the immunotherapy response. Moreover, the use of various tumor-infiltrating and circulating TRBV/J genes predicted the immunotherapy response. Our results indicate the importance of evaluating tissue and circulating TCR β repertoire prior immunotherapy, showing it as a promising immunotherapy response biomarker in NSCLC patients.

1 Introduction

2 According to the latest estimates from the International Agency for Research on Cancer (IARC), 3 lung cancer is the most common and deadliest cancer worldwide [1]. Regarding its histology, it 4 can be classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). 5 NSCLC accounts for 85% of cases and is further subdivided into adenocarcinoma, squamous 6 cell carcinoma, and large cell carcinoma [2-4]. Although environmental exposures (such as 7 fuels, arsenic, radon, and air pollution) and medical conditions (as chronic obstructive 8 pulmonary disease, HIV infection, or presence of driver mutations), contribute to its incidence 9 and mortality, smoking is the main risk factor associated with lung cancer [2,3,5].

10 NSCLC is a highly heterogeneous disease with nonspecific symptoms, leading to a common late 11 diagnosed at advanced stages (III-IV), where surgery is not feasible [2,4,5]. This greatly 12 compromise the patient's prognosis, which is clearly reflected in the 5-year survival rate, 13 decreasing from 60% in early stages to 4-6% in metastatic settings [2,4,5]. In fact, 90% of 14 cancer deaths are due to metastasis [6].

15 Nowadays, targeted therapy against many actionable mutations (EGFR, ALK, RET, BRAF, ROS1, 16 NTRK, MET, HER2 and KRAS) represent the standard treatment for molecularly defined 17 populations [2,7]. Unfortunately, only 25% of patients carry any of these mutations [2,8]. In 18 2015, the combination of immunotherapy based on immune checkpoint inhibitors (ICIs) and 19 chemotherapy (CTX) as first-line treatment significantly improved overall survival (OS) in 20 NSCLC patients compared to those treated with CTX alone [2,9,10]. Thus, ICIs has been 21 established as the standard treatment for patients with advanced NSCLC who do not have 22 actionable mutations, either as monotherapy or in combination with CTX, leading to a 5-year 23 survival rate up to 20% [2,9,10]. Unfortunately, only a small percentage of patients (20-40%) 24 benefit from it [2,9,10]. Its high cost, the limited time for therapy selection, and the possibility 25 of developing autoimmune-related side effects (such as inflammatory arthritis, colitis and 26 pneumonitis) underscore the importance of identifying those patients who can truly benefit 27 from the treatment [2,9,10].

Currently, PD1/PD-L1 immunostaining is the only approved predictive biomarker for immunotherapy response, so patients with a tumor proportion score (TPS) \geq 50% are classified as PD-L1 positive and thus, expected to respond [2,9–11]. However, its reproducibility has been limited by the heterogeneity of results obtained in subsequent studies, largely due to lack of standardization (calculation systems, thresholds, and use of different antibodies) [2,9– 11]. Over time, other alternatives such as tumor mutational burden (TMB), tumor-infiltrating

lymphocytes (TILs) and other molecular characteristics have been proposed, but none have
 been able to reliably predict patient response in the real clinical practice [2,9–11].

36 Although the antitumor response is mediated by different cellular populations, cytotoxic T cells 37 play a key role by recognizing neoantigens and killing cancer cells [12,13]. Neoantigens are recognized by the T cell receptors (TCRs). This transmembrane glycoprotein is composed of an 38 39 α and a β chain in T $\alpha\beta$ cells (95%) or by a γ and a δ chain in T $\gamma\delta$ cells (5%). Its synthesis occurs 40 through a somatic, stochastic, and imprecise recombination of various non-contiguous 41 homologous gene sets during T cell differentiation in the thymus [11,13–17]. Each chain 42 consists of a variable and a constant region. The variable region of the α and y chains results 43 from recombination between the V and J genes, while β and δ chains results from 44 recombination between the V, D, and J genes. The result of this V(D)J recombination creates a 45 variable domain that is transcribed and joins one of the constant genes (C), resulting in a functional chain. Each chain contains three hypervariable loops (CDR1, CDR2, and CDR3) in its 46 47 structure, with CDR3 mediating peptide recognition and thus determining TCR specificity 48 [11,13–17]. CDR3 is encoded by V(D)J genes and undergoes a series of random nucleotide insertions and deletions (N) during recombination at gene junctions (VN(D)NJ). This entire 49 50 process ensures the creation of a vast array of unique TCRs capable of recognizing a wide 51 range of antigens [11,13–17].

Considering its key role in neoantigen recognition, TCR repertoire analysis provides valuable 52 53 information about the antitumor response [11,12,14,15,18,19]. Furthermore, advancements in 54 sequencing technologies and bioinformatics tools have enabled sensitive and precise 55 characterization of TCR repertoire in various types of tumors, including NSCLC, making it feasible to study as a potential biomarker for immunotherapy response [11,14,15,18,19]. In 56 57 recent years, various studies have suggested the potential use of the TCR repertoire as a 58 biomarker for immunotherapy response, both for anti-CTLA4 and anti-PD-L1/PD1 therapies in 59 different types of cancer (such as melanoma, breast and liver), including NSCLC [20–39]. These 60 studies have yielded contradictory results but indicate a potential capacity for the TCR repertoire to be used as an immunotherapy response biomarker. Consequently, the main 61 62 objective of this study is to evaluate the potential of TCR repertoire analysis as a biomarker for 63 response to immunotherapy in patients with advanced NSCLC.

64 Materials and Methods

65 Study design and sample collection

66 This study included twelve patients diagnosed with advanced (IIIA-IVB) NSCLC treated with 67 pembrolizumab either as first-line (N = 11) or second-line treatment (N = 1) at Álvaro 68 Cunqueiro Hospital in Vigo. The study was conducted with appropriate authorization from the Galician Regional Research Ethics Committee (2019/046) following the Helsinki Declaration of 69 70 1975 and all patients signed informed consent approving their participation. Patients were 71 classified as responders (R: those showing complete/partial response or stable disease) and 72 non-responders (NR: those with tumor progression or unable to be evaluated due to death) 73 regarding the Response Evaluation Criteria for Solid Tumours (RECIST) [40] at 3 months. To 74 determine both tumor and peripheral TCR repertoire, formalin-fixed paraffin-embedded (FFPE) 75 tissue samples were obtained from all patients prior to immunotherapy and blood samples 76 were drawn from 10 out of 12 patients before the first ICIs dose. Peripheral blood 77 mononuclear cells (PBMCs) were isolated from blood samples by gradient density 78 centrifugation using Ficoll[®] (Sigma-Aldrich) and cryopreserved until use. DNA was chosen over 79 RNA for analysis due to its superior stability in FFPE samples.

80 **DNA Extraction**

DNA extraction from PBMCs was performed using the QIAamp[®] DNA Blood Mini Kit (QIAGEN) following the manufacturer's instructions. DNA from FFPE samples was extracted using the AllPrep[®] DNA/RNA FFPE Kit (QIAGEN) following the manufacturer's instructions. DNA quantification was carried out using NanoDropTM 2000c Spectrophotometer (Thermo Fisher Scientific).

86 Library preparation and TCR sequencing

A total of 250 ng of genomic DNA was used to prepare the libraries for TCR CDR3β/γ region
sequencing following the Oncomine[™] TCR Pan-Clonality Assay (Thermo Fisher Scientific). This
targeted next-generation sequencing (NGS) assay has been specifically designed to sequence
the FR3-J regions of the TCR beta and TCR gamma chains. Libraries were pooled on an Ion 540
chip at 25 pmol/L and sequenced using an Ion GeneStudio S5 Plus Series (Thermo Fisher
Scientific).

93 Data analysis

After sequencing, data analysis was conducted using Ion Reporter version 5.20.2.0 (Thermo
Fisher Scientific). Regarding quality control, off target and unproductive reads were removed.
Read classification is shown in *Supp. File S1*. Afterwards, the software reported the VDJ
rearrangements and the main repertoire metrics, such as richness, convergence, diversity, and

98 evenness. TCR richness represented the total number of clones, defined as unique TCR 99 beta/gamma nucleotide sequences. TCR convergence was determined as the aggregate 100 frequency of clones which shared a variable gene and CDR3 amino acid sequence. Diversity 101 (Shannon's diversity) and evenness (normalized Shannon's diversity) were calculated using the 102 formulas below, in which p_i is the frequency of clone *i* for the sample with *n* unique clones. 103 Evenness describes how evenly distributed is the TCR repertoire. It ranges from 0, meaning the 104 repertoire is unbalanced by a reduced number of predominant clones, to 1, meaning the 105 repertoire is balanced with similar frequencies of all the clones.

106 Shannon's diversity (H) =
$$-\sum_{i=1}^{n} p_i \log(p_i)$$

107 Evenness (E) =
$$\frac{H}{\log n}$$

In addition, clones were classified according to their relative abundance in the repertoire, named total clonal space, for each sample. We divided it into top 1% clonal space, top 3% clonal space and top 5% clonal space, so the top 1% clonal space is defined as the aggregate frequencies of the top 1% most frequent clones. All the variables were categorized as "high" or "low" based on their median value.

113 Statistical analysis

114 Statistical analyses were performed using R-Studio version 2023.12.0 and Bioconductor version 115 3.19 environment. Statistical significance was considered by an overall p-value < 0.05. TCR 116 repertoire variables were correlated with clinical-pathological data (age, sex, tumor histology, 117 PD1/PD-L1 expression, and smoking status), clinical response and survival data (OS and PFS). OS was defined as the time from treatment initiation to death or last follow-up, and PFS was 118 119 defined as time from treatment initiation to progression or death (whichever is earlier), or last 120 follow-up. Mann-Whitney U test and Student's t-tests were used to study the relationship 121 between TCR repertoire variables and clinical-pathological data and clinical response. Choice 122 of appropriate test (Mann-Whitney or Student's t) was based on normality (Shapiro-Wilk test) 123 and variance homogeneity (Levene test). Spearman rank non-parametric test was used for 124 variable correlations. Contingency table analyses when comparing clinical-pathological data 125 with clinical response or clinical-pathological data with TCR repertoire variables were done 126 using Fisher exact test. Kaplan-Meier survival analyses and Log-Rank test were used for timedependent variables such as OS and PFS. Receiver operating characteristics (ROC) curve 127 128 analyses were performed to evaluate response prediction, and area under the curve (AUC),

129 sensitivity and specificity values were obtained. The Youden Index method was used to select

the best cut-off values [41]. Random Forest Analysis (number of trees = 1000) was used to

131 evaluate the combined predictive signatures performances.

132 **Results**

133 Age is associated with immunotherapy response and tumor-infiltrating evenness

This retrospective observational study included a total of twelve patients diagnosed with locally advanced or advanced NSCLC (IIIA-IVB) treated with pembrolizumab at first-line (N = 11) or second-line (N = 1). The most relevant clinico-pathological characteristics are represented in *Table 1*. None of the patients had actionable mutations. Both tissue (N = 12) and PBMCs (N = 10) samples were collected before treatment and were subjected to TCR sequencing. We obtained valid TCR data in all cases (100%).

First, we evaluated the effect of immunotherapy response on patient prognosis. As expected, R had statistically significant longer PFS (p = 0.015) than NR (*Fig. 1A*). We found the same trend regarding OS (p = 0.057) (*Supp. File S2A*). Interestingly, we detected an association between response and age, where R were statistically significant older than NR (p = 0.008; R age range = 71-81 years; NR age range = 43-71 years) (*Fig. 1B*). All R were above the median age of the cohort (70.5 years) (*Supp. File S2B*). No other association was detected between clinicopathological characteristics and response or prognosis.

Second, we sought for possible associations between the clinico-pathological characteristics and TCR repertoire characterization. We detected that squamous tumors presented statistically significant higher tumor-infiltrating TCR β convergence (p = 0.026) than adenocarcinomas (*Fig. 1C*). Furthermore, we found an association between age and tumorinfiltrating evenness in both TCR β and TCR γ , where younger patients (<71 years old) had statistically significant higher tumor-infiltrating evenness than older patients (≥ 71 years old) (p = 0.022 and p = 0.041, respectively) (*Fig. 1D-E*).

Tumor-infiltrating TCRβ evenness is associated with immunotherapy response and
 Progression-Free Survival (PFS)

156 When comparing tumor tissues, we found that R had statistically significant lower tumor-157 infiltrating TCR β evenness than NR (p = 0.044) (*Fig. 2A*). Thus, its ability of potentially 158 predicting the response and survival of these patients was analysed. As represented in *Fig. 2B*, 159 tumor-infiltrating TCR β evenness predicted response with an AUC of 0.86, where a tumor-160 infiltrating TCR β evenness lower than 0.795 had a 60% sensitivity and 100% specificity of

161 predicting response. Moreover, patients with low tumor-infiltrating TCR β evenness (< 0.8441) 162 had statistically significant longer PFS than patients with high (≥ 0.8441) tumor-infiltrating 163 TCR β evenness (p = 0.013) (Fig. 2C). Similarly, we found the same trend regarding circulating 164 TCR β evenness (p = 0.139) (*Fig. 2D*). Despite they did not reach the statistical significance the 165 same trends were found regarding TCRy in both tissue and blood, respectively (p = 0.149 and p 166 = 0.114), showing a lower evenness in R patients (Fig. 2E-F). It is worth to mention that R 167 patients showed a tendency to a higher tumor-infiltrating and circulating TCRB top 3% and top 168 5% clonal space compared with NR patients (Supp. File S3A-D). Accordingly, TCRB evenness 169 and top 3% and 5% clonal space were always strongly negatively correlated both in tissue (R = -170 0.81, p = 0.001; R = -0.91, p < 0.001, respectively) and blood (R = -0.99, p < 0.001; R = -0.97, p < 171 0.001, respectively) (Supp. File S4). No other association was detected between clinico-172 pathological characteristics and TCR repertoire variables.

Tumor-infiltrating and circulating TCRβ TRBV and TRBJ genes usage is associated with immunotherapy response and Progression-Free Survival

175 Next, we sought for any relation between TRBV/TRGV and TRBJ/TRGJ genes frequencies and 176 the immunotherapy response. Regarding TCRy, there was no association between TRGV and 177 TRGJ genes frequency and clinical response, neither in tissue nor in blood. Interestingly, 178 tumor-infiltrating TCRB TRBV6.5, TRBV11.3 and TRBJ2.1 genes frequencies were statistically 179 significant lower in R than in NR (Table 2; p = 0.011, p = 0.048 and p = 0.002, respectively). 180 Moreover, circulating TCRB TRBV5.3 gene frequency was statistically significant higher in R 181 than in NR (p = 0.019), while TRBV27, TRBV28, TRBJ2.1 and TRBJ2.6 genes frequencies were 182 statistically significant lower in R than in NR (p = 0.039, p = 0.029, p = 0.017, and p = 0.008, 183 respectively), as shown in Table 3.

184 Then, we analysed their ability of potentially predict the PFS and the immunotherapy response 185 in these patients. As represented in Fig. 3A, patients with low tumor-infiltrating TCRB 186 TRBV11.3 gene frequency presented statistically significant longer PFS than patients with high 187 frequency (p = 0.002). Tumor-infiltrating TCR β TRBV11.3 gene frequency predicted response 188 with an AUC of 0.86, where a lower frequency than 0.0057 had an 80% sensitivity and 85.7% 189 specificity predicting response (Fig. 3B). In the same line, but not reaching the statistical 190 significance (p = 0.051), patients with low tumor-infiltrating TCR β TRBJ2.1 gene frequency had 191 higher PFS than patients with high frequency (Fig. 3C). Tumor-infiltrating TCRβ TRBJ2.1 gene 192 frequency predicted response with an AUC of 0.94, where a lower frequency than 0.0460 had an 100% sensitivity and 85.7% specificity predicting response (Fig. 3D). Moreover, patients 193

with low circulating TCR β *TRBJ2.6* gene frequency had statistically significant higher PFS than patients with high frequency (p = 0.003) (*Fig. 3E*). Circulating TCR β *TRBJ2.6* gene frequency predicted response with an AUC of 1.00, where a lower frequency than 0.0055 had an 100% sensitivity and 100% specificity predicting response (*Fig. 3F*). Regarding the other genes, despite most of them showed a clear tendency predicting PFS, they did not reach the statistical significance, as represented in *Supp. File S5*. In fact, most of them predicted response with high AUC (0.88-0.96) (*Supp. File S6*).

201 Combined TCRβ signatures to predict response

Although some of these TRBV/TRBJ genes did not reach the statistical significance in predicting
 PFS, they were still able to accurately predict the clinical response. Based on this observation,
 we decided to develop two predictive signatures that combine the previously described tumor infiltrating or circulating TCRβ variables associated with clinical response.

206 For the tissue predictive signature, we included variables such as evenness, TRBV6.5, 207 TRBV11.3, and TRBJ2.1. By performing Random Forest analyses, this signature was able to 208 predict clinical response with an AUC of 0.83. A positive result from this signature had a 209 sensitivity of 100% and a specificity of 71.4% in predicting response (Fig. 4A). In contrast, the 210 predictive signature for blood samples included the variables TRBV5.3, TRBV27, TRBV28, 211 TRBJ2.1, and TRBJ2.6. After conducting Random Forest analyses, this signature demonstrated a 212 predictive ability with an AUC of 0.92. In this case, a positive result had a sensitivity of 75% and 213 a specificity of 100% in predicting response (*Fig. 4B*).

These findings highlight the potential of using combined TCRβ variables to create effective
predictive signatures for both tissue and blood, aiding in the accurate prediction of clinical
response.

217 Discussion

218 ICI-based immunotherapy is the standard treatment for advanced NSCLC patients who lack of 219 actionable mutations and cannot undergo surgery. Despite ICIs have significantly improved 220 both life expectancy and quality of life for patients who benefit from it, the response rate is 221 still low (20-40%) [2,9,10]. To date, the lack of a reliable predictive response biomarkers leads 222 to the fact that most of patients are treated with ICIs, highlighting the huge need of identifying 223 those patients who can truly benefit from the treatment and offer alternative treatments to 224 the others [2,9,10]. Recently, the study of the TCR repertoire has emerged as a potential 225 predictive biomarker for immunotherapy response in various types of cancer (such as lung,

226 melanoma, liver or breast) [20–39]. It is noteworthy and important to consider the lack of 227 methodological standardization. Although most of the starting materials, technologies, library 228 preparation approaches, statistical methods and bioinformatics tools used are valid and 229 approved, the combination of all these factors generates variability that greatly complicates 230 the comparison of results [15,18,19,42,43]. Therefore, in this study we employed a reliable and 231 efficient commercial kit for library preparation, along with user-friendly and practical software 232 designed to work with FFPE samples, which are commonly used by clinicians. Additionally, we 233 opted to use DNA instead of RNA due to its superior stability, a particularly important 234 consideration when working with FFPE samples [18,42,43].

235 To the best of our knowledge this is the first study sequencing the tumor-infiltrating and 236 circulating TCR β/γ repertoire at baseline in advanced NSCLC patients treated with 237 immunotherapy. Most studies regarding the TCR repertoire have focused solely on $T\alpha\beta$ cells 238 [20-26,29-32,34-39], with very few studying the Ty δ cells, especially in solid tumors [27,28]. 239 Although the mechanism of action of Ty& cells is still not precisely known and they represent 240 only a small portion of the T cell population, it has been shown that they can play an important 241 role in antitumor response in both systemic and local immunosurveillance [14,17,27,28,33]. 242 For this reason, we decided to include also the y chain in this work. Moreover, many studies 243 have analysed the TCR repertoire dynamics before and after treatment [20,23,25,26,30-244 32,34,37,39], providing valuable insights into the mechanisms behind the antitumor response reactivation. However, most advanced NSCLC patients do not survive long enough to start a 245 246 second-line therapy. Thus, the study of the TCR repertoire as a biomarker for ICIs response 247 should be applicable before the first-line treatment. Therefore, this study focused on the TCR 248 repertoire at baseline.

249 In this study, we included 12 advanced NSCLC patients treated with ICIs at first and second 250 line. Our results confirmed that R achieved greater PFS, with the same trend observed for OS. 251 Interestingly, we found that R were older than NR. On the contrary, a comprehensive 252 comparative analysis using a cohort of anti-PD1-treated patients with renal cell carcinoma 253 identified no statistically significant difference in PFS or OS with age [44]. However, due the 254 limited numbers of older patients treated with ICIs available for their analyses there is a need 255 for further investigation of this subject in other cancer types, including NSCLC [44]. We also 256 found older patients had a lower TCR β/γ evenness in tissue but not in blood. In concordance, 257 Erbe et al. reported a decrease in tissue TCR evenness with age in patients with 258 adenocarcinoma [44]. Moreover, Dong et al. did not find such an association regarding blood

either [32]. On the contrary, following a different methodology, Liu et al. found that circulating
TCRβ diversity was lower in older patients (>60 years) [26].

261 Regarding the histological classification and the TCR repertoire, previous studies showed 262 contradictory associations. For instance, some studies described how patients with squamous 263 cell carcinomas had lower tumor-infiltrating TCR β evenness [24,38], clonal richness [38] or 264 diversity [24] compared to patients with adenocarcinoma. In contrast, and as far as we know 265 for the first time, we observed squamous had higher tumor-infiltrating TCRβ convergence than 266 adenocarcinomas, while others did not find any association between histology and any TCR 267 repertoire metric [31,32]. Although it should be verified in larger cohorts, this disparity might 268 be due to our cohort containing only three squamous cell carcinomas.

269 Previous studies showed smoking can inhibit T cell proliferation and that smoking duration negatively correlates with TCR evenness [32,38]. While some studies found lower circulating 270 271 TCRB clonal richness in smokers [32], others noted higher tumor-infiltrating TCRB evenness in 272 never-smokers [24]. However, other studies found no association between TCR metrics and 273 smoking [21,29]. Discrepancies may arise from how former smokers are classified. Given that 274 smoking effects persist long-term, we included former smokers with smokers. Due to having 275 only one non-smoker in our cohort, we lacked the statistical power to assess smoking's impact 276 on TCR repertoire metrics.

277 Our results showed that R exhibit low tumor-infiltrating TCR^β evenness at baseline, as well as 278 been able of predicting a longer PFS. This could be due to the clonal expansion of the clones 279 mediating the response. Concordant findings were also found in clear cell renal cell carcinoma, 280 where R were observed to have lower tumor-infiltrating TCR β evenness at baseline [39]. 281 Moreover, Casarrubios et al. reported a high tumor-infiltrating TCRB top 1% clonal space and a 282 low evenness at baseline were involved in a pro-inflammatory tumor microenvironment 283 associated with the complete pathological response of partially advanced stage NSCLC patients 284 treated with neoadjuvant chemo-immunotherapy [34]. Additionally, they described how these 285 same top 1% clones expanded in peripheral blood after treatment, suggesting a possible role 286 of systemic immunosurveillance in preventing relapse. Despite us and Zhang et al., found this 287 same trend regarding circulating TCR^β there is no study reporting such association 288 [20,30,32,34,35,39].

In our case, as well as in other studies [26,30,32,34], we did not find any association between
 TCRβ diversity at baseline and the clinical response. On the contrary, other studies observed
 patients with greater circulating TCRβ diversity at baseline showed a better response and

longer PFS to ICIs + CTX or ICIs alone, highlighting the role of cytotoxic T cells in the antitumor
response [25,31,35]. A possible explanation for this disparity could be that in peripheral blood,
the abundance of tumor-specific T cell may be diluted by other factors (age, antigen exposure,
or immunosuppression), affecting especially the diversity.

296 After studying the TCR β gene usage regarding the response and the PFS to immunotherapy, 297 we found some of them (TRBV5.3, TRBV6.5, TRBV11.3, TRBV27, TRBV28, TRBJ2.1 and TRBJ2.6) 298 were associated with the immunotherapy response either regarding tissue or blood. Besides, 299 TRBV11.3 and TRBJ2.6 also predicted PFS. Interestingly, R had a higher circulating TCRB 300 TRBV5.3 than NR. This could be due some of the neoantigens commonly expressed in the 301 tumor presented high affinity for the sequence encode by this gene. As consequence, it would 302 promote the recognition and eliminations of the tumor cells, mediating the antitumoral 303 response. Similarly, Dong et al. reported a circulating TCRβ low TRBV6.5 and high TRBV20.1 at 304 baseline showed a longer PFS and OS [32]. Plus, TRBV20.1 has been reported previously as one 305 of the most used TCRB V-gene in tumor-infiltrating T cells in several solid tumors [45]. 306 Therefore, it seems the TRBV/J gene usage is also, being able predict the response both in 307 tissue and blood. However, it is not clear which genes are more decisive, if there are ones.

Consequently, we decided to combine all the variables associated with response either in a tumor-infiltrating or circulating predictive signature using a random forest classifier. In both cases, they predicted the response accurately (AUC of 0.83 with 100% sensitivity and 71.4% specificity for tissue, and AUC of 0.92 with 75% sensitivity and 100% specificity for blood), suggesting that a combined signature could be more reliable than a specific variable to predict immunotherapy response.

314 Regarding TCRy, we detected the same trend found in TCRB repertoire without reaching the 315 statistical significance, where R had a lower tumor-infiltrating and circulating TCRy evenness at 316 baseline than NR. However, we did not find association between TCR variables or V/J genes usage and immunotherapy response. Although a high number of distinct TCR $\gamma\delta$ can 317 318 theoretically be generated, certain rearrangements and chain pairings are substantially over-319 represented, biasing V(D)J recombination and the selection of functional clones [14]. This leads 320 to various oligoclonal populations predominating in the circulation and in different tissues. 321 Furthermore, there is minimal knowledge reported to date regarding the TCRy repertoire as an 322 immunotherapy response biomarker [27,28], so further validation will be necessary to verify 323 these findings and draw more definitive conclusions.

324 It is noteworthy that in our study, we described both tumor-infiltrating and circulating TCRB 325 gene usage is associated with response and PFS, although different genes are present in each 326 compartment. One possible explanation is that a group of $T\alpha\beta$ cells clones had recognized a 327 series of neoantigens, expanding in peripheral blood and started infiltrating into the tumor, 328 which would explain the low TCR^β evenness found in the tissue. However, some of the clones 329 were remaining in circulation due to the expression of immune checkpoints by the tumor cells. 330 This would change with treatment, allowing all the clones to identify these cancer cells as 331 malignant, thereby promoting their complete infiltration and the elimination of the target. The 332 fact of finding potential biomarkers in blood is particularly important because, although the 333 tumor-infiltrating TCR repertoire can provide more detailed information about the immune 334 response, it can be biased by biopsy due to intratumoral heterogeneity [7,8]. Additionally, 335 finding minimally invasive circulating biomarkers that are easily measurable throughout 336 therapy would facilitate their implementation in daily clinical practice, as the number of recent 337 studies has demonstrated [23,25,26,31,32,35].

338 Conclusions

339 In summary, although much remains to be understood about the antitumor response, this 340 study highlights the potential of TCR β repertoire analysis as a potential biomarker of response 341 to immunotherapy in NSCLC patients, as we found various tumor-infiltrating and circulating 342 TCRβ variables at baseline able to predict response and progression-free survival. However, 343 the present retrospective observational study is primarily exploratory, aiming to generate 344 hypotheses rather than confirm them definitively. Consequently, further validation in larger 345 cohorts will be necessary to substantiate these findings and for better understanding of the 346 dynamics of the antitumor response.

347 Data accessibility

The datasets supporting the findings of this study are available from the corresponding authorsupon reasonable request.

350 Author contributions

351 MPG performed formal analytics and statistical analysis and wrote the manuscript. MLQ 352 enrolled patients, reviewed the clinical data annotations and wrote the manuscript. IAA 353 performed and optimized DNA isolation and libraries preparation. MGG gave analytics and 354 statistical analysis support. LJM evaluated tissue availability for FFPE sample selection. AFF

reviewed the clinical data annotations. SCF and EJL performed TCR sequencing. MMF conceived and designed the study, provided supervision and oversight for the management and execution of this study, acquired financial support for the project, and correct the manuscript. All authors provided critical review, edited the manuscript, and approved the final version.

360 Acknowledgements

Authors thank all the enrolled patients and their families. Samples were collected and storedby the Galicia Sur Health Research Institute (IIS Galicia Sur) Biobank (registry B.0000802).

363 Funding sources and disclosure of conflicts of interest

This work was supported by the Instituto de Salud Carlos III (ISCIII) and the European Social Fund ("Investing in your future") (PI21/00348, CP20/00188). MPG is currently supported by a grant for the predoctoral stage (IN606A-2024/017) from the Axencia Galega de Innovación-GAIN, Xunta de Galicia. MGG is currently supported by a grant for the postdoctoral stage (IN606B-2024/014) from the Axencia Galega de Innovación-GAIN, Xunta de Galicia. MMF is currently supported by the Miguel Servet program (CP20/00188) from the Instituto de Salud Carlos III (ISCIII).

371 The authors declare no competing interests.

372 **References**

- 373 1 Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer
- 374 statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
- in 185 countries. *CA A Cancer J Clinicians*. 2024;**74**(3):229–263.
- Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-smallcell lung cancer. *Nat Med*. 2021;**27**(8):1345–1356.
- 378 3 Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and
 future trends. *Nat Rev Clin Oncol*. 2023;**20**(9):624–639.
- 4 Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy:
 progress, pitfalls, and promises. *Mol Cancer*. 2023;**22**(1):40.

382 5 Padinharayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M, et al. Non-383 small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in 384 early diagnostics and therapeutics. Genes & Diseases. 2023;10(3):960-989. 385 6 Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a 386 hallmark of cancer revisited. Sig Transduct Target Ther. 2020;5(1):28. 387 7 Tomasik B, Skrzypski M, Bieńkowski M, Dziadziuszko R, Jassem J. Current and future 388 applications of liquid biopsy in non-small-cell lung cancer—a narrative review. Transl Lung 389 Cancer Res. 2023;12(3):594-614. 390 8 Yang Y, Liu H, Chen Y, Xiao N, Zheng Z, Liu H, et al. Liquid biopsy on the horizon in 391 immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. 392 *Cell Death Dis.* 2023;**14**(3):230. 393 9 Dugage MR, Albarrán-Artahona V, Laguna JC, Chaput N, Vignot S, Besse B, et al. Biomarkers 394 of response to immunotherapy in early stage non-small cell lung cancer. European Journal 395 of Cancer. 2023;S0959804923000783. 396 10 Oitabén A, Fonseca P, Villanueva MJ, García-Benito C, López-López A, Garrido-Fernández A, 397 et al. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. 398 Cancers. 2022;14(11):2626. 399 11 Luo H, Wang W, Mai J, Yin R, Cai X, Li Q. The nexus of dynamic T cell states and immune 400 checkpoint blockade therapy in the periphery and tumor microenvironment. Front

401 *Immunol*. 2023;**14**:1267918.

402 12 Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into
403 tumour immunogenicity and immune evasion. *Nat Rev Cancer*. 2021;**21**(5):298–312.

404 13 Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. *Sig Transduct Target Ther*.
405 2023;8(1):235.

406 14 Mensurado S, Blanco-Domínguez R, Silva-Santos B. The emerging roles of γδ T cells in
 407 cancer immunotherapy. *Nat Rev Clin Oncol*. 2023;**20**(3):178–191.

408 15 Sanromán ÁF, Joshi K, Au L, Chain B, Turajlic S. TCR sequencing: applications in immuno 409 oncology research. *Immuno-Oncology and Technology*. 2023;**17**:100373.

15

- 410 16 Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cancer immunotherapy with γδ T
- 411 cells: many paths ahead of us. *Cell Mol Immunol*. 2020;**17**(9):925–939.
- 412 17 Hu Y, Hu Q, Li Y, Lu L, Xiang Z, Yin Z, et al. γδ T cells: origin and fate, subsets, diseases and
- immunotherapy. *Sig Transduct Target Ther*. 2023;**8**(1):434.
- 414 18 Porciello N, Franzese O, D'Ambrosio L, Palermo B, Nisticò P. T-cell repertoire diversity:
- friend or foe for protective antitumor response? *J Exp Clin Cancer Res*. 2022;**41**(1):356.
- 416 19 Joshi K, Milighetti M, Chain BM. Application of T cell receptor (TCR) repertoire analysis for
- 417 the advancement of cancer immunotherapy. *Current Opinion in Immunology*. 2022;**74**:1–8.
- 20 Zhang L. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for
 Cancer. *Frontiers in Immunology*. 2020;**10**.

21 Wang Y, Peng L, Zhao M, Xiong Y, Xue J, Li B, et al. Comprehensive analysis of T cell receptor
repertoire in patients with KRAS mutant non-small cell lung cancer. *Transl Lung Cancer Res.*2022;**11**(9):1936–1950.

22 Joshi K, De Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, et al. Spatial heterogeneity
of the T cell receptor repertoire reflects the mutational landscape in lung cancer. *Nat Med*.
2019;**25**(10):1549–1559.

426 23 Sheng J, Wang H, Liu X, Deng Y, Yu Y, Xu P, et al. Deep Sequencing of T-Cell Receptors for

- 427 Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non–Small-Cell Lung Cancer
- 428 Patients Treated With the Anti–PD-L1 Antibody. *Front Mol Biosci*. 2021;**8**:679130.
- 429 24 Reuben A, Zhang J, Chiou S-H, Gittelman RM, Li J, Lee W-C, et al. Comprehensive T cell
 430 repertoire characterization of non-small cell lung cancer. *Nat Commun*. 2020;**11**(1):603.
- 431 25 Nakahara Y, Matsutani T, Igarashi Y, Matsuo N, Himuro H, Saito H, et al. Clinical significance
- 432 of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with
- 433 anti-PD-1 antibody. *Cancer Immunol Immunother*. 2021;**70**(10):2881–2892.
- 26 Liu Y, Yang Q, Yang J, Cao R, Liang J, Liu Y, et al. Characteristics and prognostic significance
 of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung
 cancer. *Int J Cancer.* 2019;**145**(5):1423–1431.

437 27 Janssen A, Villacorta Hidalgo J, Beringer DX, Van Dooremalen S, Fernando F, Van Diest E, et

- 438 al. γδ T-cell Receptors Derived from Breast Cancer–Infiltrating T Lymphocytes Mediate
- 439 Antitumor Reactivity. *Cancer Immunology Research*. 2020;**8**(4):530–543.
- 440 28 Hunter S, Willcox CR, Davey MS, Kasatskaya SA, Jeffery HC, Chudakov DM, et al. Human liver
- 441 infiltrating $\gamma\delta$ T cells are composed of clonally expanded circulating and tissue-resident
- 442 populations. *Journal of Hepatology*. 2018;**69**(3):654–665.
- 443 29 Hu Q, Frank ML, Gao Y, Ji L, Peng M, Chen C, et al. Spatial heterogeneity of T cell repertoire
- across NSCLC tumors, tumor edges, adjacent and distant lung tissues. *Oncolmmunology*.
 2023;**12**(1):2233399.
- 446 30 Han J, Yu R, Duan J, Li J, Zhao W, Feng G, et al. Weighting tumor-specific TCR repertoires as
- 447 a classifier to stratify the immunotherapy delivery in non–small cell lung cancers. *Sci Adv*.
- 448 2021;**7**(21):eabd6971.
- 449 31 Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, et al. TCR Repertoire Diversity of Peripheral
- 450 PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–
- 451 Small Cell Lung Cancer. *Cancer Immunology Research*. 2020;**8**(1):146–154.
- 452 32 Dong N, Moreno-Manuel A, Calabuig-Fariñas S, Gallach S, Zhang F, Blasco A, et al.
- 453 Characterization of Circulating T Cell Receptor Repertoire Provides Information about
- 454 Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients.
- 455 *Cancers*. 2021;**13**(12):2950.
- 33 Davey MS, Willcox CR, Joyce SP, Ladell K, Kasatskaya SA, McLaren JE, et al. Clonal selection
 in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune
 surveillance. *Nat Commun.* 2017;8(1):14760.
- 459 34 Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo M del R, Lázaro M, et al.
- 460 Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic
- 461 Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. *Clinical*
- 462 *Cancer Research*. 2021;**27**(21):5878–5890.
- 463 35 Abed A, Beasley AB, Reid AL, Law N, Calapre L, Millward M, et al. Circulating pre-treatment
- 464 T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-
- 465 cell lung cancer patients treated with pembrolizumab alone or in combination with
- 466 chemotherapy. *ESMO Open*. 2023;**8**(6):102066.

- 467 36 Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, et al.
- 468 Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for
- 469 Immunotherapy against Melanoma. *Cancer Immunology Research*. 2019;**7**(1):77–85.
- 470 37 Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, et al. CTLA4 Blockade Broadens
- 471 the Peripheral T-Cell Receptor Repertoire. *Clinical Cancer Research*. 2014;**20**(9):2424–2432.
- 472 38 Kargl J, Busch SE, Yang GHY, Kim K-H, Hanke ML, Metz HE, et al. Neutrophils dominate the
- immune cell composition in non-small cell lung cancer. *Nat Commun*. 2017;**8**(1):14381.
- 474 39 Au L, Hatipoglu E, Robert De Massy M, Litchfield K, Beattie G, Rowan A, et al. Determinants
- 475 of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer Cell*.
- 476 2021;**39**(11):1497-1518.e11.
- 477 40 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response
- 478 evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European*
- 479 *Journal of Cancer*. 2009;**45**(2):228–247.
- 480 41 Youden WJ. Index for rating diagnostic tests. *Cancer*. 1950;**3**(1):32–35.
- 481 42 Barennes P, Quiniou V, Shugay M, Egorov ES, Davydov AN, Chudakov DM, et al.
- 482 Benchmarking of T cell receptor repertoire profiling methods reveals large systematic
- 483 biases. *Nat Biotechnol*. 2021;**39**(2):236–245.
- 484 43 Chiffelle J, Genolet R, Perez MA, Coukos G, Zoete V, Harari A. T-cell repertoire analysis and
- 485 metrics of diversity and clonality. *Current Opinion in Biotechnology*. 2020;**65**:284–295.
- 44 Erbe R, Wang Z, Wu S, Xiu J, Zaidi N, La J, et al. Evaluating the impact of age on immune
 checkpoint therapy biomarkers. *Cell Reports*. 2021;**36**(8):109599.
- 488 45 Li B, Li T, Pignon J-C, Wang B, Wang J, Shukla SA, et al. Landscape of tumor-infiltrating T cell
 489 repertoire of human cancers. *Nat Genet*. 2016;**48**(7):725–732.
- 490
- 491
- 492
- 493

494 Tables

495 Table 1: Clinico-pathologic characteristics of patients.

Clinico-pathologic characteristics	Responders (N = 5)	Non-responders (N = 7)	Cohort (N = 12)
Age (years)			
Median (range)	74 (71-81)	60 (43-71)	70.5 (43-81)
Sex			
Male	4	5	9
Female	1	2	3
Smoking status			
Smoker	2	4	6
Former smoker	3	2	5
Never smoker	0	1	1
Histology			
Squamous	2	1	3
Adenocarcinoma	3	6	9
Stage			
IIIA	0	1	1
IIIC	0	1	1
IVA	4	0	4
IVB	1	5	6
PD1/PD-L1 staining			
Positive	4	6	10
Negative	1	1	2
Response type			
СР	0	0	0
PR	3	0	3
SD	2	0	2
PD	0	4	4
NE	0	3	3
PFS (days)			
Median (range)	328 (116-952)	72 (3-148)	100 (4-952)
OS (days)			
Median (range)	405 (126-952)	113 (4-364)	225 (4-952)

496 ADC: adenocarcinoma, CR: complete response, N: number of patients, NE: non-evaluable. PD: progressive disease,

497 PFS: Progression-free survival, PR: partial response, SCC: squamous cell carcinoma, SD: stable disease, OS: overall
498 survival.

499

500

501

502

503

504 Table 2: Tumor-infiltrating TCR^β TRBV and TRBJ genes frequency in responder (R) compared to non-responders (NR).

Varia	ble	Responder (N = 5)	Non-responder (N = 7)	p-value
TRBV6.5	Median	0.0082	0.0359	0.011*
TRBV11.3	Median	0.0054	0.0077	0.048*
TRBJ2.1	Median	0.0230	0.0581	0.002**

505	P-value was obtained using Student's t test. N: number of patients, *: statistically significance, **: strongly
506	statistically significance.
507	
508	
509	
510	
511	
512	
513	
514	
515	
510	
518	
519	
520	
521	
522	
523	
524	
525	

- 526 Table 3: Circulating TCRB TRBV and TRBJ genes frequency in responder (R) compared to non-responder (NR). N,
- 527 *number; *, statistically significance; **, very statistically significance.*

Variable		Responder (N = 4) Non-responder (N = 6		p-value
TRBV5.3	Median	0.0003	0.0001	0.019*
TRBV27	Median	0.0423	0.0897	0.039*
TRBV28	Median	0.0176	0.0633	0.029*
TRBJ2.1	Median	0.0257	0.0662	0.017*
TRBJ2.6	Median	0.0032	0.0092	0.008**

528 *P*-value was obtained using Student's t test. N: number of patients, *: statistically significance, **: strongly 529 statistically significance.

530			
531			
532			
533			
534			
535			
536			
537			
538			
539			
540			
541			
542			
543			
544			
545			
546			

547 Figure legends

548 Figure 1: A) Responders (R) have statistically significant longer PFS than non-responders (NR) (p = 0.015). P-value 549 was obtained using Log-Rank test. B) There are an association between response and age, where R are statistically 550 significant older than NR (p = 0.008). P-value was obtained using Student's t test. C) Squamous have statistically 551 significant higher tumor-infiltrating TCR β convergence than adenocarcinomas (p = 0.026). P-value was obtained 552 using Mann-Whitney test. D) Younger patients (< 71 years old) have statistically significant higher tumor-infiltrating 553 TCR6 evenness than older patients (\geq 71 years old) (p = 0.022). P-value was obtained using Student's t test. E) 554 Younger patients have statistically significant higher tumor-infiltrating TCRy evenness than older patients (p =555 0.041). P-value was obtained using Mann-Whitney test. N: number of patients, PFS: progression-free survival, *:

556 statistically significance, **: strongly statistically significance.

557 Figure 2: A) Responders (R) have statistically significant lower tumor-infiltrating TCRB evenness than non-responders 558 (NR) (p = 0.044). P-value was obtained using Student's t test. B) Tumor-infiltrating TCRB evenness predicts response 559 with an AUC of 0.86. A lower tumor-infiltrating TCRB evenness than 0.795 have a 60% sensitivity and 100% 560 specificity predicting response. C) Patients with low tumor-infiltrating TCRB evenness have statistically significant 561 higher PFS than patients with high tumor-infiltrating TCR6 evenness (p = 0.013). P-value was obtained using Log-562 Rank test. D) R have a non-statistically significant lower circulating TCR8 evenness than NR (p = 0.139). P-value was 563 obtained using Student's t test. E) R have a non-statistically significant lower tumor-infiltrating TCRy evenness than 564 NR (p = 0.149). P-value was obtained using Mann-Whitney test. F) R have a non-statistically significant lower 565 circulating TCRy evenness than NR (p = 0.114). P-value was obtained using Mann-Whitney test. AUC: Area Under the 566 Curve, N: number of patients, PFS: progression-free survival, *: statistically significance.

567 Figure 3: A) Patients with low tumor-infiltrating TCR6 TRBV11.3 gene frequency have statistically significant higher 568 PFS than patients with high tumor-infiltrating TCR8 TRBV11.3 gene frequency (p = 0.002). P-value was obtained 569 using Log-Rank test. B) Tumor-infiltrating TCR8 TRBV11.3 gene frequency predicts response with an AUC of 0.86. A 570 lower tumor-infiltrating TCR6 TRBV11.3 gene frequency than 0.0057 have an 80% sensitivity and 85.7% specificity 571 predicting response. C) Patients with low tumor-infiltrating TCR6 TRBJ2.1 gene frequency have non-statistically 572 significant higher PFS than patients with high tumor-infiltrating TCR8 TRBJ2.1 gene frequency (p = 0.051). P-value 573 was obtained using Log-Rank test. D) Tumor-infiltrating TCR6 TRBJ2.1 gene frequency predicts response with an 574 AUC of 0.94. A lower tumor-infiltrating TCRB TRBJ2.1 gene frequency than 0.0460 have an 100% sensitivity and 575 85.7% specificity predicting response. E) Patients with low circulating TCR6 TRBJ2.6 gene frequency have statistically 576 significant higher PFS than patients with high circulating TCR6 TRBJ2.6 gene frequency (p = 0.003). P-value was 577 obtained using Log-Rank test. F) Circulating TCR6 TRBJ2.6 gene frequency predicts response with an AUC of 1.00. A 578 lower circulating TCR8 TRBJ2.6 gene frequency than 0.0055 have an 100% sensitivity and 100% specificity predicting 579 response. AUC: Area Under the Curve, N: number of patients, PFS: progression-free survival, *: statistically 580 significance, **: strongly statistically significance.

Figure 4: A) A predictive signature including tumor-infiltrating TCR6 variables (evenness, TRBV6.5 gene frequency,
TRBV11.3 gene frequency and TRBJ2.1 gene frequency) predicts response with an AUC of 0.83. A positive result has
an 100% sensitivity and 71.4% specificity predicting response. B) A predictive signature including circulating TCR6
variables (TRBV5.3 gene frequency, TRBV27 gene frequency, TRBV28 gene frequency, TRBJ2.1 gene frequency and
TRBJ2.6 gene frequency) predicts response with an AUC of 0.92. A positive result has an 75% sensitivity and 100%
specificity predicting response. AUC: Area Under the Curve.





589 Figure 2



591 Figure 3



595

596 **Figure 4**









